Evaluation of new drugs in small cell lung cancer: the activity of gemcitabine.
The evaluation of the activity of new drugs against small cell lung cancer (SCLC) is discussed and the results with gemcitabine are presented. Gemcitabine has activity against untreated SCLC. Preliminary results from an ongoing study also indicate activity in so-called resistant SCLC.
Postmus
P E
PE
Department of Pulmonary Diseases, University Hospital, Vrije Universiteit, Amsterdam, The Netherlands.
Schramel
F M
FM
Smit
E F
EF
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine